One must keep in mind that in the present study, the non-TTP TMA incidence is an approximation based on the postulate that ADAMTS-13 activity testing is a first line analysis prescribed for any patient with a suspected TMA, in order to differentiate TTP from any other non-TTP TMA. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.